RareCyte is a Seattle-based precision biology company that develops advanced platforms and services for spatial biology and liquid biopsy. Its technologies are used by academic institutions, biopharma companies, and contract research organizations to accelerate biomarker development and advance precision medicine research.

What is the Orion spatial proteomics platform?

Orion is RareCyte's spatial proteomics platform that enables single-round high-plex immunofluorescence imaging of tissue samples. It captures up to 18 biomarkers in a single round, delivering high-fidelity spatial data for translational and clinical research.

What is the CyteFinder platform used for?

The CyteFinder platform is designed for circulating tumor cell (CTC) detection, characterization, and single-cell retrieval from blood samples. It is used in global oncology clinical trials and supports liquid biopsy programs including companion diagnostic development.

What precision biology services does RareCyte offer?

RareCyte offers end-to-end precision biology services including custom assay development, clinical trial sample testing, and biomarker research services. Its labs are CLIA-certified and ISO 13485-certified. The company has delivered hundreds of custom assays to over 100 biopharma and academic partners.

Where is RareCyte located?

RareCyte is headquartered in Seattle, Washington at 2601 Fourth Avenue, Suite 500.

RareCyte — High-Plex Spatial Proteomics at Clinical Research Scale

Enabling high-confidence precision biology

RareCyte develops advanced spatial biology and liquid biopsy technologies that deliver the reliable data researchers need to accelerate biomarker development and advance precision biology at clinical scale.

High-plex Spatial Biology

High-sensitivity Liquid Biopsy

Two platforms advancing translational and clinical research

Orion™ Spatial Proteomics

The Orion spatial proteomics platform delivers the multiplex depth, throughput, and reproducible data quality researchers need to advance biomarker programs.

Explore Orion

CyteFinder® Rare Cell Detection

Designed for CTC monitoring in global clinical trials, the CyteFinder platform accurately and reproducibly phenotypes as few as 1 CTC per tube of blood.

Explore CyteFinder

Why customers choose RareCyte

RareCyte technologies are designed to enable biomarker development at clinical scale.

Purpose-driven innovation

Paradigm-shifting technologies
High sensitivity, plex, and throughput
Accurate, reproducible clinical workflows

High-confidence data

Ultra-sensitive detection
Sample chain-of-custody
Reproducible results at scale

Built for clinical research

Cohort-scale biomarker programs
Rapid, custom panel development
Any sample, any indication

Precision Biology™ Services

Accelerate your biomarker programs with custom assay development, clinical trial testing, and biomarker research services — powered by RareCyte technologies.

Trusted Partner

A proven partner to over 100 biopharma and leading academic institutions, delivering hundreds of custom assays to support biomarker development across diverse indications.

Accredited Infrastructure

To meet the quality requirements of our customers, the RareCyte quality management system includes an accredited CLIA Laboratory following GLP guidelines, LIMS and eQMS systems for sample and documentation management, along with an ISO13485:2016 accreditation for product manufacturing.

Start your program

Trusted by leading researchers

"We are excited to offer multiplex immunofluorescence for clinical trial biomarker testing leveraging the powerful Orion HT technology. The platform's ability to deliver high-plex data at scale is exactly what our programs require."

Jennifer Bordeaux, PhD

Associate Director | Digital Pathology Solutions | Navigate Biopharma Services, Inc.

“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”

Jeff Fill

Sr. Director, Diagnostic and Experimental Pathology | Eli Lilly and Company

“Every Pathology field has a set of molecular questions that have remained unanswered, and now we have the tool that can provide the answers."

Sandro Santagata, MD, PhD

Associate Director, Laboratory of Systems Pharmacology | Harvard Medical School

"Advanced spatial biology has shed new light on therapeutic research in immuno-oncology. The data quality and reproducibility we've achieved with Orion has been transformative for our biomarker discovery programs."

Zhihong Chen PhD

CTO | OCCAM Immune | Icahn School of Medicine, Mount Sinai

“Using their liquid biopsy technology, RareCyte was able to develop a custom assay. Throughout the process, the RareCyte team was collaborative and insightful, showing true dedication to the project, resulting in the development of a fully validated assay.”

Erica Tobin

Associate Director, Oncology | KSQ Therapeutics, Inc.

"This technology [CyteFinder] can detect as few as one cell in a sample."

Daniel E. Sabath, MD, PhD

Professor | Head, Hematology Division, Department of Laboratory Medicine | University of Washington

"One advantage of Orion is staining 17 antibodies all at once. Compared to cyclic IF, you don’t have to do stripping which can lead to antigen [and tissue] degradation, so the detection of the antigen is optimal. In addition, you don't have to design the position of the antibodies in the cycle. This technology saves time."

Yuna Delarue

Laboratory Technician | CHU de Brest

Ready to advance your research?

Speak with our team about how RareCyte platforms and services can accelerate your program.

Book a meeting Explore Orion

Introducing Orion™ HT

The new standard for spatial
biomarker development

Enabling high-confidence precision biology

Two platforms advancing translational and clinical research